The CEO As R&D Chief – An Interview With Carl Zeiss’ Michael Kaschke
Executive Summary
Given the importance of rapid and persistence technology development in medical devices, why is it that so few medtech CEOs come from R&D? Michael Kaschke, president and CEO of Carl Zeiss, is the exception that proves the rule. Kaschke joined the company in 1992 and began a steady ascent through the management ranks. In an interview, adapted from a recent session in the Innovator’s Workbench series sponsored by the BioDesign Program at Stanford University, Kaschke talks about Zeiss and its strong R&D culture, about how his own background in technology development shapes his approach to decision-making and about the challenges the company has faced in the past and the ones it faces going forward.
You may also be interested in...
J&J’s New Path Forward – An Interview With Alex Gorsky
In his last interview before becoming CEO of Johnson & Johnson, Alex Gorsky talks about the changes that J&J has made recently in its medical device business and discusses his upcoming promotion to head of all of J&J.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.